Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

A Review on the Efficacy and Safety of Intrathecal Administration of Novel Medications for Leptomeningeal Metastases in Solid Cancers

Author(s): Fatemeh Jafari, Mohammad Moeini Nodeh, Hesamoddin Hosseinjani, Hamed Baharara, Sajad Azad, Omid Arasteh*, Thomas P. Johnston and Amirhossein Sahebkar*

Volume 31, Issue 19, 2024

Published on: 14 June, 2023

Page: [2732 - 2750] Pages: 19

DOI: 10.2174/0929867330666230508142657

Price: $65

Abstract

Leptomeningeal disease (LMD) is a rare and lethal manifestation that may occur in the advanced stages of solid tumors and hematological malignancies. With advances in diagnostic techniques, the detection and confirmation of the presence of LMD have increased. Although its optimal treatment remains a challenge, the use of the intrathecal route for the delivery of novel therapeutics is now considered a promising drug delivery strategy to complement radiation and systemic-based therapies. Although methotrexate, cytarabine, and thiotepa have a long history in the treatment of LMD, other medications have also been shown to be beneficial. In this article, we have reviewed the effects of novel medications administered via the intrathecal route for the treatment of solid tumors. We have searched PubMed, Scopus, and Google Scholar databases till the end of September 2021 using the following keywords: “leptomeningeal disease”, “leptomeningeal carcinomatosis”, “leptomeningeal metastases”, “solid tumors”, “solid cancers”, and “intrathecal”. Our literature findings have uncovered that most studies on LMD, which occurs secondary to solid cancers, are available as ‘case reports’, and few clinical trials have been conducted to date. Single-drug (monotherapy) or combination drug therapy, administered via the intrathecal route, especially in metastatic breast and lung cancer, has been shown to improve patients' symptoms and overall lifespan, while exhibiting a low and acceptable prevalence of side effects. However, judgments/conclusions about the effectiveness and safety of these drugs still require further clinical evaluation.

« Previous Next »
[1]
Byun, Y.H.; Gwak, H.S.; Kwon, J.W.; Kim, K.G.; Shin, S.H.; Lee, S.H.; Yoo, H. A novel implantable cerebrospinal fluid reservoir: A pilot study. J. Korean Neurosurg. Soc., 2018, 61(5), 640-644.
[http://dx.doi.org/10.3340/jkns.2018.0098] [PMID: 30196661]
[2]
Thakkar, J.P.; Kumthekar, P.; Dixit, K.S.; Stupp, R.; Lukas, R.V. Leptomeningeal metastasis from solid tumors. J. Neurol. Sci., 2020, 411, 116706.
[http://dx.doi.org/10.1016/j.jns.2020.116706] [PMID: 32007755]
[3]
Alexis Demopoulos, M.; Paul Brown, M. Treatment of leptomeningeal metastases (carcinomatous meningitis). 2018.
[4]
Carausu, M.; Carton, M.; Darlix, A.; Pasquier, D.; Leheurteur, M.; Debled, M.; Mouret-Reynier, M.A.; Goncalves, A.; Dalenc, F.; Verret, B.; Campone, M.; Augereau, P.; Ferrero, J.M.; Levy, C.; Fumet, J.D.; Lefeuvre-Plesse, C.; Petit, T.; Uwer, L.; Jouannaud, C.; Larrouquere, L.; Chevrot, M.; Courtinard, C.; Cabel, L. Breast cancer patients treated with intrathecal therapy for leptomeningeal metastases in a large real-life database. ESMO Open, 2021, 6(3), 100150.
[http://dx.doi.org/10.1016/j.esmoop.2021.100150] [PMID: 33984675]
[5]
Nguyen, T.K.; Nguyen, E.K.; Soliman, H. An overview of leptomeningeal disease. Ann. Palliat. Med., 2020.
[PMID: 32921068]
[6]
Le Rhun, E.; Preusser, M.; van den Bent, M.; Andratschke, N.; Weller, M. How we treat patients with leptomeningeal metastases. ESMO Open, 2019, 4(S2), e000507.
[http://dx.doi.org/10.1136/esmoopen-2019-000507] [PMID: 31231573]
[7]
Clarke, J.L.; Perez, H.R.; Jacks, L.M.; Panageas, K.S.; DeAngelis, L.M. Leptomeningeal metastases in the MRI era. Neurology, 2010, 74(18), 1449-1454.
[http://dx.doi.org/10.1212/WNL.0b013e3181dc1a69] [PMID: 20439847]
[8]
Clarke, J.L. Leptomeningeal metastasis from systemic cancer. Continuum (Minneap. Minn.), 2012, 18(2), 328-342.
[http://dx.doi.org/10.1212/01.CON.0000413661.58045.e7] [PMID: 22810130]
[9]
White, M.D.; Klein, R.H.; Shaw, B.; Kim, A.; Subramanian, M.; Mora, J.L. Detection of leptomeningeal disease using cell-free DNA from cerebrospinal fluid. JAMA Netw Open, 2021, 4(8), e2120040.
[http://dx.doi.org/10.1001/jamanetworkopen.2021.20040]
[10]
Li, Y.; Pan, W.; Connolly, I.D.; Reddy, S.; Nagpal, S.; Quake, S. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J. Neurooncol., 2016, 128, 93-100.
[http://dx.doi.org/10.1007/s11060-016-2081-5]
[11]
Pellerino, A.; Bertero, L.; Rudà, R.; Soffietti, R. Neoplastic meningitis in solid tumors: From diagnosis to personalized treatments. Ther. Adv. Neurol. Disord., 2018, 11
[http://dx.doi.org/10.1177/1756286418759618] [PMID: 29535794]
[12]
Thomas, K.H.; Ramirez, R.A. Leptomeningeal disease and the evolving role of molecular targeted therapy and immunotherapy. Ochsner J., 2017, 17(4), 362-378.
[PMID: 29230121]
[13]
de Oca Delgado, M.M.; Cacho, D.B.; Santos, Z.J.; Guerrero, J.V.; López, M.M.S.; Castro, M.E.; Méndez-Padilla, A.J.; Mejía, P.S.; Reyes, M.I.; Gutiérrez, A.A.; González, A.A. The comparative treatment of intraventricular chemotherapy by Ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front. Oncol., 2018, 8, 509.
[http://dx.doi.org/10.3389/fonc.2018.00509] [PMID: 30524956]
[14]
Rueda, D.A.; Olmos, H.D.; Viciana, G.R.; Torres, S.E. Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis. Clin. Transl. Oncol., 2005, 7(6), 232-238.
[15]
Vergoulidou, M. Leptomeningeal carcinomatosis in gastric cancer: A therapeutical challenge. Biomark. Insights, 2017, 12
[http://dx.doi.org/10.1177/1177271917695237] [PMID: 28469397]
[16]
Yamasaki, T.; Fukui, H.; Sei, H.; Hara, K.; Eda, H.; Kondo, T.; Toyoshima, F.; Kono, T.; Tozawa, K.; Ikehara, H.; Tomita, T.; Oshima, T.; Watari, J.; Miwa, H. Efficacy of intrathecal MTX/Ara-C combined with systemic chemotherapy in a gastric cancer patient with meningeal carcinomatosis. Intern. Med., 2016, 55(6), 609-611.
[http://dx.doi.org/10.2169/internalmedicine.55.5129] [PMID: 26984076]
[17]
Yamakawa, H.; Ariga, H.; Enomoto, A.; Netsu, S.; Suzuki, Y.; Konno, R. Meningeal dissemination from an ovarian carcinoma with effective response to intrathecal chemotherapy. Int. J. Clin. Oncol., 2009, 14(5), 447-451.
[http://dx.doi.org/10.1007/s10147-008-0846-3] [PMID: 19856055]
[18]
Oh, S.Y.; Lee, S.J.; Lee, J.; Lee, S.; Kim, S.H.; Kwon, H.C.; Lee, G.W.; Kang, J.H.; Hwang, I.G.; Jang, J.S.; Lim, H.Y.; Park, Y.S.; Kang, W.K.; Kim, H.J. Gastric leptomeningeal carcinomatosis: Multi-center retrospective analysis of 54 cases. World J. Gastroenterol., 2009, 15(40), 5086-5090.
[http://dx.doi.org/10.3748/wjg.15.5086] [PMID: 19860003]
[19]
Huppert, L.A.; Melisko, M.E.; Glastonbury, C.M.; Khanafshar, E.; Daud, A.I. Treatment of metastatic melanoma with leptomeningeal disease using intrathecal immunotherapy. JCO Oncol. Pract., 2020, 16(11), 757-759.
[http://dx.doi.org/10.1200/OP.20.00146] [PMID: 32603255]
[20]
Glitza, I.C.; Rohlfs, M.L.; Iqbal, M.; Richard, J.; Burton, E.; Duncan, S.; Brown, C.; Anderson, J.; Hwu, P.; Hwu, W-J.; Wong, M.; Yee, C.; Patel, S.; Woodman, S.; Amaria, R.; Diab, A.; Tawbi, H.; Davies, M. A phase I/Ib study of concurrent intravenous (IV) and intrathecal (IT) nivolumab (Nivo) for melanoma patients (pts) with leptomeningeal disease (LMD). Ann. Oncol., 2018, 29, viii464.
[http://dx.doi.org/10.1093/annonc/mdy289.057]
[21]
John, I.; Foster, A.P.; Haymaker, C.L.; Bassett, R.L.; Lee, J.J.; Rohlfs, M.L. Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD). J. Clin. Oncol., 2021, 39(15)
[http://dx.doi.org/10.1200/JCO.2021.39.15_suppl.9519]
[22]
Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; Rodríguez-Cid, J.; Wilson, J.; Sugawara, S.; Kato, T.; Lee, K.H.; Cheng, Y.; Novello, S.; Halmos, B.; Li, X.; Lubiniecki, G.M.; Piperdi, B.; Kowalski, D.M. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N. Engl. J. Med., 2018, 379(21), 2040-2051.
[http://dx.doi.org/10.1056/NEJMoa1810865] [PMID: 30280635]
[23]
Khoja, L.; Butler, M.O.; Kang, S.P.; Ebbinghaus, S.; Joshua, A.M. Pembrolizumab. J. Immunother. Cancer, 2015, 3(1), 36.
[http://dx.doi.org/10.1186/s40425-015-0078-9] [PMID: 26288737]
[24]
Schmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kümmel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; Takahashi, M.; Foukakis, T.; Fasching, P.A.; Cardoso, F.; Untch, M.; Jia, L.; Karantza, V.; Zhao, J.; Aktan, G.; Dent, R.; O’Shaughnessy, J. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med., 2020, 382(9), 810-821.
[http://dx.doi.org/10.1056/NEJMoa1910549] [PMID: 32101663]
[25]
Naidoo, J.; Schreck, K.; Fu, W.; Hu, C.; Connolly, R.; Santa-Maria, C. Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. J. Immunother. Cancer, 2020, 9(8), e002473.
[26]
Brastianos, P.K.; Lee, E.Q.; Cohen, J.V.; Tolaney, S.M.; Lin, N.U.; Wang, N.; Chukwueke, U.; White, M.D.; Nayyar, N.; Kim, A.; Alvarez-Breckenridge, C.; Krop, I.; Mahar, M.K.; Bertalan, M.S.; Shaw, B.; Mora, J.L.; Goss, N.; Subramanian, M.; Nayak, L.; Dietrich, J.; Forst, D.A.; Nahed, B.V.; Batchelor, T.T.; Shih, H.A.; Gerstner, E.R.; Moy, B.; Lawrence, D.; Giobbie-Hurder, A.; Carter, S.L.; Oh, K.; Cahill, D.P.; Sullivan, R.J. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med., 2020, 26(8), 1280-1284.
[http://dx.doi.org/10.1038/s41591-020-0918-0] [PMID: 32483359]
[27]
Ensign, S.P.F.; Yancey, E.; Anderson, K.S.; Mrugala, M.M. Safety and feasibility of intrathecal pembrolizumab infusion in refractory triple negative breast cancer with leptomeningeal disease: A case report. Current Problems in Cancer: Case Reports, 2021, 4, 100103.
[http://dx.doi.org/10.1016/j.cpccr.2021.100103]
[28]
Boland, W.K.; Bebb, G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin. Biol. Ther., 2009, 9(9), 1199-1206.
[http://dx.doi.org/10.1517/14712590903110709] [PMID: 19624281]
[29]
Jiao, S.; Ju, Y.; Wang, J.; Sun, S. Nimotuzumab treatment and outcome analysis in patients with leptomeningeal metastasis from nonsmall cell lung cancer. J. Cancer Res. Ther., 2016, 12(S7), 181.
[http://dx.doi.org/10.4103/0973-1482.200596] [PMID: 28230014]
[30]
Figura, N.B.; Rizk, V.T.; Armaghani, A.J.; Arrington, J.A.; Etame, A.B.; Han, H.S.; Czerniecki, B.J.; Forsyth, P.A.; Ahmed, K.A. Breast leptomeningeal disease: A review of current practices and updates on management. Breast Cancer Res. Treat., 2019, 177(2), 277-294.
[http://dx.doi.org/10.1007/s10549-019-05317-6] [PMID: 31209686]
[31]
McKeage, K.; Perry, C.M. Trastuzumab. Drugs, 2002, 62(1), 209-243.
[http://dx.doi.org/10.2165/00003495-200262010-00008] [PMID: 11790161]
[32]
Keefe, D.L. Trastuzumab-associated cardiotoxicity. Cancer, 2002, 95(7), 1592-1600.
[http://dx.doi.org/10.1002/cncr.10854] [PMID: 12237930]
[33]
Curigliano, G; Mueller, V; Borges, V; Hamilton, E; Hurvitz, S; Loi, S Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis. Ann Oncol, 2022, 33(3), 321-329.
[34]
Ferrario, C.; Davidson, A.; Bouganim, N.; Aloyz, R.; Panasci, L.C. Intrathecal trastuzumab and thiotepa for leptomeningeal spread of breast cancer. Ann. Oncol., 2009, 20(4), 792-795.
[http://dx.doi.org/10.1093/annonc/mdp019] [PMID: 19223574]
[35]
Perissinotti, A.J.; Reeves, D.J. Role of intrathecal rituximab and trastuzumab in the management of leptomeningeal carcinomatosis. Ann. Pharmacother., 2010, 44(10), 1633-1640.
[http://dx.doi.org/10.1345/aph.1P197] [PMID: 20807868]
[36]
Figura, N.B.; Rizk, V.T.; Mohammadi, H.; Evernden, B.; Mokhtari, S.; Yu, H.M.; Robinson, T.J.; Etame, A.B.; Tran, N.D.; Liu, J.; Washington, I.; Diaz, R.; Czerniecki, B.J.; Soliman, H.; Han, H.S.; Sahebjam, S.; Forsyth, P.A.; Ahmed, K.A. Clinical outcomes of breast leptomeningeal disease treated with intrathecal trastuzumab, intrathecal chemotherapy, or whole brain radiation therapy. Breast Cancer Res. Treat., 2019, 175(3), 781-788.
[http://dx.doi.org/10.1007/s10549-019-05170-7] [PMID: 30859348]
[37]
Figura, N.B.; Long, W.; Yu, M.; Robinson, T.J.; Mokhtari, S.; Etame, A.B.; Tran, N.D.; Diaz, R.; Soliman, H.; Han, H.S.; Sahebjam, S.; Forsyth, P.A.; Ahmed, K.A. Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: A single institution experience. Breast Cancer Res. Treat., 2018, 169(2), 391-396.
[http://dx.doi.org/10.1007/s10549-018-4684-3] [PMID: 29392582]
[38]
Zagouri, F.; Sergentanis, T.N.; Bartsch, R.; Berghoff, A.S.; Chrysikos, D.; de Azambuja, E.; Dimopoulos, M.A.; Preusser, M. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: A systematic review and pooled analysis. Breast Cancer Res. Treat., 2013, 139(1), 13-22.
[http://dx.doi.org/10.1007/s10549-013-2525-y] [PMID: 23588955]
[39]
Lu, N.T.; Raizer, J.; Gabor, E.P.; Liu, N.M.; Vu, J.Q.; Slamon, D.J.; Barstis, J.L. Intrathecal trastuzumab: Immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient. J. Immunother. Cancer, 2015, 3(1), 41.
[http://dx.doi.org/10.1186/s40425-015-0084-y] [PMID: 26380087]
[40]
Stemmler, H.J.; Schmitt, M.; Harbeck, N.; Willems, A.; Bernhard, H.; Lässig, D.; Schoenberg, S.; Heinemann, V. Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol. Rep., 2006, 15(5), 1373-1377.
[PMID: 16596213]
[41]
Lombardi, G.; Zustovich, F.; Farina, P.; Della Puppa, A.; Manara, R.; Cecchin, D.; Brunello, A.; Cappetta, A.; Zagonel, V. Neoplastic meningitis from solid tumors: New diagnostic and therapeutic approaches. Oncologist, 2011, 16(8), 1175-1188.
[http://dx.doi.org/10.1634/theoncologist.2011-0101] [PMID: 21795431]
[42]
Carmichael, J.; Possinger, K.; Phillip, P.; Beykirch, M.; Kerr, H.; Walling, J.; Harris, A.L. Advanced breast cancer: A phase II trial with gemcitabine. J. Clin. Oncol., 1995, 13(11), 2731-2736.
[http://dx.doi.org/10.1200/JCO.1995.13.11.2731] [PMID: 7595731]
[43]
Von Hoff, D.D.; Ervin, T.; Arena, F.P.; Chiorean, E.G.; Infante, J.; Moore, M.; Seay, T.; Tjulandin, S.A.; Ma, W.W.; Saleh, M.N.; Harris, M.; Reni, M.; Dowden, S.; Laheru, D.; Bahary, N.; Ramanathan, R.K.; Tabernero, J.; Hidalgo, M.; Goldstein, D.; Van Cutsem, E.; Wei, X.; Iglesias, J.; Renschler, M.F. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med., 2013, 369(18), 1691-1703.
[http://dx.doi.org/10.1056/NEJMoa1304369] [PMID: 24131140]
[44]
Chen, Y.M.; Chen, M.C.; Tsai, C.M.; Perng, R.P. Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis—a case report. Lung Cancer, 2003, 40(1), 99-101.
[http://dx.doi.org/10.1016/S0169-5002(02)00504-4] [PMID: 12660014]
[45]
Bernardi, R.J.; Bomgaars, L.; Fox, E.; Balis, F.M.; Egorin, M.J.; Lagattuta, T.F.; Aikin, A.; Whitcomb, P.; Renbarger, J.; Lieberman, F.S.; Berg, S.L.; Blaney, S.M. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother. Pharmacol., 2008, 62(2), 355-361.
[http://dx.doi.org/10.1007/s00280-007-0601-x] [PMID: 17909804]
[46]
Miao, Q.; Zheng, X.; Zhang, L.; Jiang, K.; Wu, B.; Lin, G. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis. Ann. Palliat. Med., 2020, 9(6), 4233-4245.
[http://dx.doi.org/10.21037/apm-20-2086] [PMID: 33302683]
[47]
Ma, Y.; Liu, H.; Zhang, M.; Liu, B.; Ding, Q.; Zhang, L. Successful treatment using targeted therapy, radiotherapy, and intrathecal chemotherapy in a patient with leptomeningeal metastasis with an epidermal growth factor receptor exon 20 insertion mutation: A case report. Ann. Palliat. Med., 2021, 11(4), 1533-1541.
[PMID: 34263612]
[48]
Fan, C.; Zhao, Q.; Li, L.; Shen, W.; Du, Y.; Teng, C.; Gao, F.; Song, X.; Jiang, Q.; Huang, D.; Jin, Y.; Lv, Y.; Wei, L.; Shi, T.; Zhao, X.; Gao, N.; Jiang, Z.; Xin, T. Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-Mutant NSCLC—a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615). J. Thorac. Oncol., 2021, 16(8), 1359-1368.
[http://dx.doi.org/10.1016/j.jtho.2021.04.018] [PMID: 33989780]
[49]
Li, H.; Lin, Y.; Yu, T.; Xie, Y.; Feng, J.; Huang, M.; Guo, A.; Liu, X.; Yin, Z. Treatment response to intrathecal chemotherapy with pemetrexed via an Ommaya reservoir in EGFR-mutated leptomeningeal metastases from non-small cell lung cancer: A case report. Ann. Palliat. Med., 2020, 9(4), 2341-2346.
[http://dx.doi.org/10.21037/apm-19-521] [PMID: 32648459]
[50]
Pan, Z.; Yang, G.; Cui, J.; Li, W.; Li, Y.; Gao, P.; Jiang, T.; Sun, Y.; Dong, L.; Song, Y.; Zhao, G. A pilot phase 1 study of intrathecal pemetrexed for refractory leptomeningeal metastases from non-small-cell lung cancer. Front. Oncol., 2019, 9, 838.
[http://dx.doi.org/10.3389/fonc.2019.00838] [PMID: 31544065]
[51]
Pan, Z.; Yang, G.; He, H.; Cui, J.; Li, W.; Yuan, T.; Chen, K.; Jiang, T.; Gao, P.; Sun, Y.; Cong, X.; Li, Z.; Wang, Y.; Pang, X.; Song, Y.; Zhao, G. Intrathecal pemetrexed combined with involved-field radiotherapy as a first-line intra-CSF therapy for leptomeningeal metastases from solid tumors: A phase I/II study. Ther. Adv. Med. Oncol., 2020, 12
[http://dx.doi.org/10.1177/1758835920937953] [PMID: 32733606]
[52]
Mazur, L.; Opydo-Chanek, M.; Stojak, M.; Wojcieszek, K. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials. Anticancer Res., 2012, 32(7), 2783-2789.
[PMID: 22753738]
[53]
Blaney, S.M.; Balis, F.M.; Berg, S.; Arndt, C.A.S.; Heideman, R.; Geyer, J.R.; Packer, R.; Adamson, P.C.; Jaeckle, K.; Klenke, R.; Aikin, A.; Murphy, R.; McCully, C.; Poplack, D.G. Intrathecal mafosfamide: A preclinical pharmacology and phase I trial. J. Clin. Oncol., 2005, 23(7), 1555-1563.
[http://dx.doi.org/10.1200/JCO.2005.06.053] [PMID: 15735131]
[54]
Salgia, S.; Fleming, G.F.; Lukas, R.V. Leptomeningeal carcinomatosis from breast cancer treated with intrathecal topotecan with concomitant intravenous eribulin. J. Clin. Neurosci., 2014, 21(7), 1250-1251.
[http://dx.doi.org/10.1016/j.jocn.2013.09.018] [PMID: 24412296]
[55]
Tran, H.C.; Gardner, S.; Weiner, H.L.; Liebes, L.F.; Finlay, J.L. Pilot study assessing a seven-day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. J. Oncol. Pharm. Pract., 2014, 20(3), 229-232.
[http://dx.doi.org/10.1177/1078155213494940] [PMID: 23929729]
[56]
Martens, J.; Venuturumilli, P.; Corbets, L.; Bestul, D. Rapid clinical and radiographic improvement after intrathecal trastuzumab and methotrexate in a patient with HER-2 positive leptomeningeal metastases. Acta Oncol., 2013, 52(1), 175-178.
[http://dx.doi.org/10.3109/0284186X.2012.689857] [PMID: 22655969]
[57]
Stemmler, H.J.; Mengele, K.; Schmitt, M.; Harbeck, N.; Laessig, D.; Herrmann, K.A.; Schaffer, P.; Heinemann, V. Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: A case report. Anticancer Drugs, 2008, 19(8), 832-836.
[http://dx.doi.org/10.1097/CAD.0b013e32830b58b0] [PMID: 18690096]
[58]
Tobin, M.K.; Geraghty, J.R.; Engelhard, H.H.; Linninger, A.A. Intramedullary spinal cord tumors: A review of current and future treatment strategies. Neurosurg. Focus., 2015, 39(2), E14.
[59]
Balmaceda, C. Chemotherapy for intramedullary spinal cord tumors. J. Neurooncol., 2000, 47(3), 293-307.
[PMID: 11016745]
[60]
Hassall, T.; Mitchell, A.E.; Ashley, DMJN-o arboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: Three case studies and a review of the literature. Neuro. Oncol., 2001, 3(4), 251.
[61]
Bell, W.O.; Packer, R.J.; Seigel, K.R.; Rorke, L.B.; Sutton, L.N.; Bruce, D.A. Leptomeningeal spread of intramedullary spinal cord tumors: Report of three cases. J Neurosurg, 1988, 69(2), 295-300.
[http://dx.doi.org/10.3171/jns.1988.69.2.0295]
[62]
Xi, W.; Junling, L.; Jianping, X.; Boyan, Y.; Lei, Y.; Xiaoming, W. Efficacy and security of intrathecal with methotrexate in the treatment of meningeal carcinomatosis. Zhongguo Fei Ai Za Zhi, 2016, 19(5), 252-256.
[PMID: 27215452]
[63]
Pan, Z.; Yang, G.; He, H.; Zhao, G.; Yuan, T.; Li, Y.; Shi, W.; Gao, P.; Dong, L.; Li, Y. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: A prospective and single-arm study. Int. J. Cancer, 2016, 139(8), 1864-1872.
[http://dx.doi.org/10.1002/ijc.30214] [PMID: 27243238]
[64]
Salkade, P.R.; Teh, A.L. Methotrexate-induced acute toxic leukoencephalopathy. J. Cancer Res. Ther., 2012, 8(2), 292-296.
[65]
Cohen, IJ; Stark, B.; Kaplinsky, C.; Weitz, R.; Matz, S.; Lerman, P. Methotrexate-induced leukoencephalopathy is treatable with high-dose folinic acid: A case report and analysis of the literature. Pediatr. Hematol. Oncol., 1990, 7(1), 79-87.
[http://dx.doi.org/10.3109/08880019009034321]
[66]
Jaeckle, K.A.; Phuphanich, S.; Bent, M.J.; Aiken, R.; Batchelor, T.; Campbell, T.; Fulton, D.; Gilbert, M.; Heros, D.; Rogers, L.; O’Day, S.J.; Akerley, W.; Allen, J.; Baidas, S.; Gertler, S.Z.; Greenberg, H.S.; LaFollette, S.; Lesser, G.; Mason, W.; Recht, L.; Wong, E.; Chamberlain, M.C.; Cohn, A.; Glantz, M.J.; Gutheil, J.C.; Maria, B.; Moots, P.; New, P.; Russell, C.; Shapiro, W.; Swinnen, L.; Howell, S.B. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br. J. Cancer, 2001, 84(2), 157-163.
[http://dx.doi.org/10.1054/bjoc.2000.1574] [PMID: 11161370]
[67]
Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F.; Howell, S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res., 1999, 5(11), 3394-3402.
[PMID: 10589750]
[68]
Grossman, S.A.; Krabak, M.J. Leptomeningeal carcinomatosis. Cancer Treat. Rev., 1999, 25(2), 103-119.
[http://dx.doi.org/10.1053/ctrv.1999.0119] [PMID: 10395835]
[69]
Scott, B.J.; van Vugt, V.A.; Rush, T.; Brown, T.; Chen, C.C.; Carter, B.S.; Schwab, R.; Fanta, P.; Helsten, T.; Bazhenova, L.; Parker, B.; Pingle, S.; Saria, M.G.; Brown, B.D.; Piccioni, D.E.; Kesari, S. Concurrent intrathecal methotrexate and liposomal cytarabine for leptomeningeal metastasis from solid tumors: A retrospective cohort study. J. Neurooncol., 2014, 119(2), 361-368.
[http://dx.doi.org/10.1007/s11060-014-1486-2] [PMID: 24942463]
[70]
Park, W.Y.; Kim, H.J.; Kim, K.; Bae, S.B.; Lee, N.; Lee, K.T.; Won, J.H.; Park, H.S.; Lee, S.C. Intrathecal trastuzumab treatment in patients with breast cancer and leptomeningeal carcinomatosis. Cancer Res. Treat., 2016, 48(2), 843-847.
[http://dx.doi.org/10.4143/crt.2014.234] [PMID: 25761487]
[71]
Comte, A.; Jdid, W.; Guilhaume, M.N.; Kriegel, I.; Piperno-Neumann, S.; Dieras, V.; Dorval, T.; Pierga, J.Y.; Cottu, P.H.; Mignot, L.; Bidard, F.C. Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepa. J. Neurooncol., 2013, 115(3), 445-452.
[http://dx.doi.org/10.1007/s11060-013-1244-x] [PMID: 24043602]
[72]
Ferguson, S.D.; Bindal, S.; Bassett, R.L., Jr; Haydu, L.E.; McCutcheon, I.E.; Heimberger, A.B.; Li, J.; O’Brien, B.J.; Guha-Thakurta, N.; Tetzlaff, M.T.; Tawbi, H.; Davies, M.A.; Glitza, I.C. Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD). J. Neurooncol., 2019, 142(3), 499-509.
[http://dx.doi.org/10.1007/s11060-019-03121-2] [PMID: 30847840]
[73]
Raizer, J.J.; Rademaker, A.; Evens, A.M.; Rice, L.; Schwartz, M.; Chandler, J.P.; Getch, C.C.; Tellez, C.; Grimm, S.A. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer, 2012, 118(15), 3743-3748.
[http://dx.doi.org/10.1002/cncr.26709] [PMID: 22179954]
[74]
Archer, G.E.; Sampson, J.H.; McLendon, R.E.; Friedman, A.H.; Colvin, O.M.; Rose, M.; Sands, H.; McCullough, W.; Fuchs, H.E.; Bigner, D.D.; Friedman, H.S. Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J. Neurooncol., 1999, 44(3), 233-241.
[http://dx.doi.org/10.1023/A:1006304424346] [PMID: 10720203]
[75]
Gururangan, S.; Petros, W.P.; Poussaint, T.Y.; Hancock, M.L.; Phillips, P.C.; Friedman, H.S.; Bomgaars, L.; Blaney, S.M.; Kun, L.E.; Boyett, J.M. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: A Pediatric Brain Tumor Consortium Study (PBTC-004). Clin. Cancer Res., 2006, 12(5), 1540-1546.
[http://dx.doi.org/10.1158/1078-0432.CCR-05-2094] [PMID: 16533779]
[76]
Sampson, J.H.; Archer, G.E.; Villavicencio, A.T.; McLendon, R.E.; Friedman, A.H.; Bishop, W.R.; Bigner, D.D.; Friedman, H.S. Treatment of neoplastic meningitis with intrathecal temozolomide. Clin. Cancer Res., 1999, 5(5), 1183-1188.
[PMID: 10353755]
[77]
Mir, O.; Ropert, S.; Alexandre, J.; Lemare, F.; Goldwasser, F. High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer. Ann. Oncol., 2008, 19(11), 1978-1980.
[http://dx.doi.org/10.1093/annonc/mdn654] [PMID: 18845838]
[78]
Oliveira, M.; Braga, S.; Passos-Coelho, J.L.; Fonseca, R.; Oliveira, J. Complete response in HER2+ leptomeningeal carcinomatosis from breast cancer with intrathecal trastuzumab. Breast Cancer Res. Treat., 2011, 127(3), 841-844.
[http://dx.doi.org/10.1007/s10549-011-1417-2] [PMID: 21369716]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy